Entyvio 300 MG vials
Ended Awarded
- Contract number
- SPE2DB25FL1R4
- Awardee
-
DMS Pharmaceutical Group Inc. UEI PX72BSBQTKJ3
- Awarding agency
-
Defense Logistics Agency
Department of Defense
- Obligated
- $98,899
Award facts
- Contract value 100% obligated
- $98,898.60 Current and potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- NAICS code
- 424210 Drugs and Druggists' Sundries Merchant Wholesalers
- PSC
- 6505 Drugs And Biologicals
- Set-aside
- No set-aside
- Competition
- Full and Open Competition Negotiated Proposal / Quote
- Pricing
- Firm Fixed Price
- Place of performance
- Park Ridge, IL 60068, USA
Award details come from SAM.gov/FPDS.
About this award
DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, was awarded a firm fixed-price delivery order valued at $98,898.60 for the supply of Entyvio 300 mg vials. The Defense Logistics Agency issued this delivery order on August 6, 2025, with an ultimate completion date of August 27, 2025. This award was made without a set-aside designation, allowing DMS Pharmaceutical Group to compete on its merits in the open federal procurement market. The delivery order represents performance at the company's Park Ridge, Illinois facility.
This delivery order is issued under DMS Pharmaceutical Group's larger Indefinite Delivery Contract with the Defense Logistics Agency under the SPE2DB program, a $499,999,999 single-award contract valid through November 2026 that enables the agency to procure a comprehensive range of pharmaceutical products for military healthcare facilities worldwide. Entyvio is a biologic medication used in the treatment of inflammatory bowel disease, and this delivery order ensures continued pharmaceutical supply support for Department of Defense healthcare operations. The company has established itself as a critical supplier in the federal pharmaceutical supply chain, with a demonstrated track record of delivering diverse pharmaceutical products including prescription medications, biologics, vaccines, and specialty pharmaceutical items to military health facilities across the nation.
Quick answers
Who was awarded contract SPE2DB25FL1R4?
SPE2DB25FL1R4 was awarded to DMS Pharmaceutical Group Inc. by Defense Logistics Agency (Department of Defense) on August 6, 2025.
How much is contract SPE2DB25FL1R4 worth?
The government has obligated $98,899 on SPE2DB25FL1R4.
Is contract SPE2DB25FL1R4 an order under another contract?
Yes. SPE2DB25FL1R4 is a delivery order under SPE2DB20D9331, an indefinite delivery contract.
Was contract SPE2DB25FL1R4 competed?
The extent of competition for SPE2DB25FL1R4 was full and open competition.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award